A day after the European Commission authorised the use of the US-based Novavax Covid-19 vaccine, the World Health Organization (WHO) on Tuesday (December 21) also approved ‘Nuvaxovid’ for emergency use, reported Agence France Presse (AFP).
The two-shot Nuvaxovid jab is the 10th Covid vaccine issued an emergency use listing (EUL) by the UN health agency.
The vaccine is made from a more conventional technology than others already approved, which has led officials in Brussels to express hope that this will help persuade those hesitant about vaccination to come forward. The jab uses a traditional technology involving proteins found on coronavirus spike proteins that trigger an immune response. It is a tried and tested approach, used for decades to vaccinate people against diseases including hepatitis B and whooping cough, according to AFP.
Notably, the EUL by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution. It also opens the door for them to enter the Covax global vaccine-sharing scheme, set up to provide equitable access to doses around the world and particularly in poorer countries.
90-percent effective
WHO said Nuvaxovid was around 90 per cent effective at reducing symptomatic cases of Covid-19 in two major clinical studies, one in Britain and the other in the United States and Mexico, involving more than 45,000 people, according to AFP.
In a separate document, WHO’s Strategic Advisory Group of Experts on Immunisation recommended the new vaccine for use in people over the age of 18, with an interval of three to four weeks between the two doses. “The vaccine should not be administered with an interval of less than three weeks,” it warned.
The vaccine can be kept at refrigerated temperatures between 2 and 8 degrees Celsius, giving it a logistical advantage in difficult-to-access regions over the mRNA vaccines, which must be stored at ultra-low temperatures.